Analysts have revised Biovica International’s fair value estimate downward from SEK 1.80 to SEK 1.20. This change reflects more cautious projections for revenue growth and profit margins.
What's in the News
- Biovica International completed a follow-on equity offering and raised SEK 80.1 million through a rights offering that included both A and B shares with attached warrants (Key Developments).
- A lock-up agreement was established for certain A shares, which prevents their sale from 1 August 2025 to 1 February 2026 following the rights issue (Key Developments).
- The company launched DiviTum TKa for early breast cancer as a laboratory developed test in the US, expanding its addressable market fivefold to approximately USD 3 billion annually (Key Developments).
- A fourth work order was secured with a major pharmaceutical client, valued at SEK 3 million, for retrospective breast cancer study testing to be completed in fall 2025 (Key Developments).
- The limits for share capital and number of shares in the articles of association were increased at the July 2025 extra general meeting (Key Developments).
Valuation Changes
- Fair Value Estimate has decreased from SEK 1.80 to SEK 1.20, reflecting a substantial downward adjustment.
- Discount Rate has risen slightly, from 4.92% to 4.97%. This indicates a more cautious risk assessment.
- Revenue Growth forecasts have fallen slightly, from 204.0% to 197.8%.
- Net Profit Margin has decreased modestly, moving from 20.44% to 19.51%.
- Future P/E Ratio has declined sharply, from 14.10x to 2.74x. This suggests a more conservative outlook on future earnings.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.